CLINICAL TRIALS PROFILE FOR ATROPINE SULFATE

All Clinical Trials for ATROPINE SULFATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	Health Region East, Norway	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	Laerdal Medical	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	Norwegian Air Ambulance Foundation	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	Ullevaal University Hospital	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	University of Oslo	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00121524 ↗	Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome	Completed	Petter Andreas Steen	Phase 2	2003-01-01	Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
NCT00458003 ↗	Phenylephrine in Spinal Anesthesia in Preeclamptic Patients	Completed	Northwestern University	N/A	2006-07-01	Hypotension remains a common clinical problem after induction of spinal anesthesia for cesarean delivery. Maternal hypotension has been associated with considerable morbidity (maternal nausea and vomiting and fetal/neonatal acidemia). Traditionally, ephedrine has been the vasopressor of choice because of concerns about phenylephrine's potential adverse effect on uterine blood flow. This practice was based on animal studies which showed that ephedrine maintained cardiac output and uterine blood flow, while direct acting vasoconstrictors, e.g., phenylephrine, decreased uteroplacental perfusion. However, several recent studies have demonstrated that phenylephrine has similar efficacy to ephedrine for preventing and treating hypotension and may be associated with a lower incidence of fetal acidosis. All of these studies have been performed in healthy patients undergoing elective cesarean delivery. Preeclampsia complicates 5-6% of all pregnancies and is a significant contributor to maternal and fetal morbidity and mortality. Many preeclamptic patients require cesarean delivery of the infant. These patients often have uteroplacental insufficiency. Given the potential for significant hypotension after spinal anesthesia and its effect on an already compromised fetus, prevention of (relative) hypotension in preeclamptic patients is important. Spinal anesthesia in preeclamptic patients has been shown to have no adverse neonatal outcomes as compared to epidural anesthesia when hypotension is treated adequately. Due to problems related to management of the difficult airway and coagulopathy, both of which are more common in preeclamptic women, spinal anesthesia may be the preferred regional anesthesia technique. Recent studies have demonstrated that preeclamptic patients may experience less hypotension after spinal anesthesia than their healthy counterparts. To our knowledge, phenylephrine for the treatment of spinal anesthesia-induced hypotension has not been studied in women with preeclampsia. The aim of our study is to compare intravenous infusion regimens of phenylephrine versus ephedrine for the treatment of spinal anesthesia induced hypotension in preeclamptic patients undergoing cesarean delivery. The primary outcome variable is umbilical artery pH.

Clinical Trial Conditions for ATROPINE SULFATE

Condition Name

Condition Name for ATROPINE SULFATE
Intervention	Trials
Myopia	10
Postoperative Pain	6
Myopia, Progressive	4
Pain, Postoperative	3

Condition MeSH

Condition MeSH for ATROPINE SULFATE
Intervention	Trials
Myopia	13
Pain, Postoperative	8
Myopia, Degenerative	4
Bradycardia	3

Clinical Trial Locations for ATROPINE SULFATE

Trials by Country

Trials by Country for ATROPINE SULFATE
Location	Trials
United States	53
China	20
Egypt	12
Brazil	4
Austria	3

Trials by US State

Trials by US State for ATROPINE SULFATE
Location	Trials
Texas	7
California	5
North Carolina	3
Colorado	3
South Carolina	3

Clinical Trial Progress for ATROPINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for ATROPINE SULFATE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	5
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ATROPINE SULFATE
Clinical Trial Phase	Trials
Completed	29
Recruiting	11
Not yet recruiting	10

Clinical Trial Sponsors for ATROPINE SULFATE

Sponsor Name

Sponsor Name for ATROPINE SULFATE
Sponsor	Trials
Mansoura University	4
Assiut University	3
Laboratorios Sophia S.A de C.V.	3

Sponsor Type

Sponsor Type for ATROPINE SULFATE
Sponsor	Trials
Other	63
Industry	21
U.S. Fed	3

ATROPINE SULFATE Market Analysis and Financial Projection

Last updated: April 24, 2026

ATROPINE SULFATE: Clinical Trials Update, Market Analysis, and Projection

What is the current clinical-trials landscape for atropine sulfate?

Atropine sulfate is an established, off-patent antimuscarinic used in multiple acute-care indications (notably bradycardia and symptomatic vagal tone), with product formulations and clinical use supported by decades of practice rather than a modern, proprietary drug-approval pipeline.

For a “clinical trials update” that is decision-grade (trial phase, enrollment, sites, primary endpoints, recruitment status, and readout dates), the available information in this chat does not include any trial registry extracts, sponsor-level filings, or date-stamped registry snapshots. Without that, a complete and accurate trial-by-trial update cannot be produced in a way that meets high-stakes R&D or investment standards.

What is the market structure for atropine sulfate?

Atropine sulfate markets are typically characterized by:

• Generic availability across multiple dosage forms (commonly injectable solutions; other formulations exist by region).
• Hospital and emergency-channel demand driven by protocol use, stock management, and clinical guidelines.
• Regulatory and supply resilience as primary value drivers, not differentiated clinical efficacy.
• Price competition as the dominant commercial force in most markets where generics hold share.

Because “atropine sulfate” is widely generic, market value is primarily a function of:

• Unit volumes in acute care (EDs, inpatient wards, anesthesia settings).
• Procurement patterns (tendering, formulary placement).
• Regulatory availability and shortages (which can drive short-term price and inventory premiums).
• Geographic mix (health system reimbursement structures).

How large is the addressable market, and where does demand concentrate?

A complete market sizing and forward projection requires at minimum one of the following: (1) an authoritative revenue baseline by geography and formulation, (2) unit-volume baselines with conversion to revenue, or (3) published market-research forecasts. None of those numeric inputs are provided in this chat.

A decision-grade market projection for atropine sulfate must not substitute generic medians or non-attributable proxies. Without a numeric baseline and consistent methodology, any projection would be unreliable.

What are the main demand drivers and commercial constraints?

Even without registry- or vendor-level numbers, the commercial dynamics for a generic injectable like atropine sulfate are usually dominated by a small set of measurable factors:

Demand drivers

• Acute-care incidence: symptomatic bradycardia, perioperative and anesthesia-associated bradycardia management, and other protocol-driven uses.
• Standardization in care pathways: frequent inclusion in emergency drug kits and perioperative carts.
• Hospital purchasing: repeat ordering based on usage rates and minimum inventory thresholds.

Commercial constraints

• Low pricing power: generics compress margin unless supply is constrained.
• Supply continuity risk: manufacturing capacity and regulatory throughput affect availability.
• Formulation and packaging: vial size, concentration, labeling, and cold-chain requirements can influence procurement decisions even when API is the same.
• Regulatory and tender cycles: contract turnovers can quickly reallocate share.

What market scenario framework can be used for projection?

A robust projection framework for atropine sulfate should anchor on three scenarios tied to observed drivers:

1. Baseline (steady procurement)

   • Demand scales with inpatient/ED volumes and stable formulary usage.
   • Pricing stays aligned with generic tender compression.

2. Supply-constrained upside

   • Manufacturing or regulatory disruptions tighten supply.
   • Hospitals reorder higher and pay premiums in constrained windows.

3. Competitive downside

   • Tender cycles push price down.
   • New entrants or lower-cost contracts shift volume away from higher-priced SKUs.

To apply this framework as a forecast, the model needs numeric inputs for current price, current unit volume, and supply constraints history. Those are not present in this chat.

What is the likely pipeline and innovation angle for atropine sulfate?

Atropine sulfate is not a typical “innovation-led” category. The competitive edge usually comes from:

• Manufacturing efficiency and yield
• Regulatory dossiers and approvals
• Packaging options aligned to hospital protocols
• Supply reliability

Clinical trial activity, when it exists, often targets:

• Formulation equivalence or clinical pharmacology in specific contexts
• Label expansions rather than new chemical entities

A full “clinical trials update” for these points requires a current registry pull.

---

Key Takeaways

• Atropine sulfate is a mature, largely generic antimuscarinic where market outcomes typically track hospital procurement behavior and supply continuity rather than a modern branded development pipeline.
• A decision-grade clinical-trials update (trial phase, recruitment status, endpoints, and dates) cannot be generated from the information available in this chat.
• A decision-grade market sizing and multi-period projection cannot be produced without a numeric baseline for revenue or unit volume and a consistent geography-by-formulation methodology.

---

FAQs

1) Is atropine sulfate still under active development with major Phase 3 programs?
Not based on the information available in this chat. Atropine sulfate is widely used and generally treated as an established therapy with generic availability.

2) What drives demand for atropine sulfate in hospitals?
Protocol-driven use in acute-care and anesthesia settings, tied to patient volume and hospital formulary stock practices.

3) Why does supply matter disproportionately for atropine sulfate?
Injectables can see abrupt pricing and allocation impacts during manufacturing or regulatory supply disruptions.

4) What kinds of “innovation” usually matter for generic atropine sulfate?
Manufacturing reliability, regulatory submissions, and packaging/formulation choices that match procurement standards.

5) Can a market forecast be made without baseline revenue or unit volume?
No, forecast integrity requires a baseline and transparent assumptions by geography and dosage form.

---

References

[1] No external sources were provided in the prompt, and no registry or market datasets were included in the available information.